Status:
UNKNOWN
PD-L1-expressing Regulatory T Cells in Localized Prostate Cancer Patients Undergoing Iodine-125 Permanent Brachytherapy
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Prostate Cancer
Eligibility:
MALE
30-90 years
Brief Summary
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer is poorly responsive to immune checkpoint inhibition. The combination of immunotherapy and radiotherapy is an...
Detailed Description
Permanent brachytherapy is one of those standard treatments for localized prostate cancer patients. Biopsy confirms prostate cancer. Blood and urine of localized prostate cancer patients will be coll...
Eligibility Criteria
Inclusion
- \- Biopsy confirms prostate cancer
- Localized Prostate Cancer, ≤cT3
- No chemotherapy or Hormonal therapy before Permanent Brachytherapy
Exclusion
- \- Unacceptable operative risk
- Poor anatomy which in the opinion of the radiation oncologist could lead to a suboptimal implant (e.g.,large or poorly healed transurethral resection of the prostate (TURP) defect, large median lobe, large gland size).
- Pathologically positive lymph nodes
- Significant obstructive uropathy
- Distant metastases
- Use steroids regularly
- The diagnosis was accompanied by immune-related diseases
- Allergic constitution
- Abnormal white blood cell and lymphocyte counts
- Ever underwent other treatments for prostate cancer, such as chemotherapy or Hormonal therapy
- Accompanied by other malignancies
- Splenectomy
- HIV positive
- Receive an anti-infective vaccine for the last 6 months
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04369508
Start Date
July 1 2020
End Date
December 31 2022
Last Update
April 30 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.